Britannia Life Sciences Inc. BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.06% | 25.50% | -92.96% | -93.37% | -93.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.06% | 25.50% | -92.96% | -93.37% | -93.38% |
| Cost of Revenue | -48.17% | -28.43% | -59.76% | -66.88% | -74.15% |
| Gross Profit | 143.00% | 170.67% | -134.99% | -115.25% | -106.05% |
| SG&A Expenses | -23.02% | -24.20% | 12.52% | -1.87% | -39.88% |
| Depreciation & Amortization | 3.87% | 5.08% | 37.42% | 104.61% | 310.28% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.27% | -24.37% | -17.00% | -29.30% | -53.41% |
| Operating Income | 34.02% | 33.07% | -199.11% | -1,445.71% | -734.65% |
| Income Before Tax | 458.96% | 398.82% | 207.56% | 59.97% | 25.34% |
| Income Tax Expenses | -- | -- | 503.36% | -- | -- |
| Earnings from Continuing Operations | 447.64% | 388.08% | 193.04% | 58.11% | 22.37% |
| Earnings from Discontinued Operations | -86.26% | -86.55% | 1,409.60% | 1,751.61% | 4,588.70% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 118.20% | 119.50% | 78.46% |
| Net Income | 132.60% | 107.55% | 345.83% | 205.41% | 228.35% |
| EBIT | 34.02% | 33.07% | -199.11% | -1,445.71% | -734.65% |
| EBITDA | 35.10% | 34.15% | -210.58% | -3,669.31% | -520.54% |
| EPS Basic | 133.02% | 107.67% | 346.01% | 205.41% | 228.05% |
| Normalized Basic EPS | 98.31% | 47.86% | 52.17% | 43.31% | 2.75% |
| EPS Diluted | 133.02% | 107.67% | 346.01% | 205.41% | 228.05% |
| Normalized Diluted EPS | 98.31% | 47.86% | 52.17% | 43.31% | 2.75% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |